Komori
ReproCELL (4978) · TargetFull-year results presented

Earnings Forecast for the Fiscal Year Ending March 2019: Revenue Growth and Narrower Losses

First written in FY2018. 3 of 5 entries say "Advanced", first in FY2019-Q1. Latest entry: FY2020-Q1.

5entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2019-Q1 – FY2019-Q32018: 320182019: 22019
Same theme, other companies
Consolidated Earnings Outlook for the Fiscal Year Ending March 2019A theme 19 companies write about · 4 as a headwind · 9 as a tailwind

11 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 19 companies compared. The sentences above are computed from all 19.
Full recordFilings, disclosures and news, newest first
  1. FY2020-Q1Full-year results presentedAnnual report

    「Revenue (¥ thousands) 254,596 256,715 1,088,527 Ordinary loss (△) (¥ thousands) △97,251 △229,633 △627,091 Quarterly net loss (net loss) attributable to owners of the parent (△) (¥ thousands) △80,213 △229,937 △601,424」

    The company presented full-year results for the fiscal year ending March 2019 of revenue of ¥1,088 million, an ordinary loss of ¥627 million and a net loss attributable to owners of the parent of ¥601 million. This filing does not state whether these results met the company's previous forecasts.
  2. FY2019-Q3AdvancedAnnual report

    「As a result, for the nine months ended the third quarter, revenue was ¥806 million, up 17.3% year on year, operating loss was ¥587 million, compared with a loss of ¥772 million in the same period of the previous year, ordinary loss was ¥456 million, compared with a loss of ¥639 million, and quarterly net loss attributable to owners of the parent was ¥430 million, compared with a loss of ¥652 million.」

    Against the forecast of revenue growth and reduced losses for the fiscal year ending March 2019, cumulative revenue for the third quarter rose 17.3% year on year, while operating, ordinary and net losses attributable to owners of the parent all narrowed from the previous year.
  3. FY2019-Q2AdvancedAnnual report

    「As a result, for the six months ended the second quarter, revenue was ¥538 million, up 20.8% year on year, operating loss was ¥405 million, compared with a loss of ¥536 million in the same period of the previous year, ordinary loss was ¥251 million, compared with a loss of ¥416 million, and quarterly net loss attributable to owners of the parent was ¥228 million, compared with a loss of ¥435 million.」

    Against the forecast of revenue growth and reduced losses for the fiscal year ending March 2019, cumulative revenue for the second quarter rose 20.8% year on year, while operating, ordinary and net losses all narrowed from the previous year.
  4. FY2019-Q1AdvancedAnnual report

    「As a result, for the first quarter of the fiscal year, revenue was ¥254 million, up 20.6% year on year, operating loss was ¥221 million, compared with a loss of ¥274 million in the same period of the previous year, ordinary loss was ¥97 million, compared with a loss of ¥196 million, and net loss attributable to owners of the parent was ¥80 million, compared with a loss of ¥200 million.」

    Against the forecast of revenue growth and reduced losses for the fiscal year ending March 2019, first-quarter revenue rose 20.6% year on year, while operating, ordinary and net losses all narrowed from the previous year.
  5. FY2018First statedAnnual report

    「For the fiscal year ending March 2019, the company forecasts revenue of ¥1,167 million, up 26.1% year on year; an operating loss of ¥757 million, compared with a loss of ¥1,025 million in the previous fiscal year; an ordinary loss of ¥709 million, compared with a loss of ¥935 million in the previous fiscal year; and a net loss attributable to owners of the parent of ¥709 million, compared with a loss of ¥2,172 million in the previous fiscal year.」

    For the fiscal year ending March 2019, the company numerically forecasts higher revenue and smaller operating, ordinary and net losses.
Moved together

"Exclusive development and marketing of Stemchymal® in Japan" moved the same way as this thread, in the same document, in 3 of its 5 moves.

332222★123456
  1. ★This thread
  2. 1Exclusive development and marketing of Stemchymal® in Japan3×
  3. 2Persistent losses as upfront investment and R&D expenses precede revenue generation3×
  4. 3Raising Funds for Cell Therapy Product Development and Clinical Trials through the 12th Series of Stock Acquisition Rights2×
  5. 4Differentiation through a broad lineup of research reagents, cell products and contract services2×
  6. 5Global expansion leveraging sales channels in Japan, the US and Europe2×
  7. 6Funding Needs and Financing Risk Associated with Research and Development and Capital Investment2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for ReproCELL yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.